We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Serum Adiponectin in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01372800
Recruitment Status : Unknown
Verified November 2011 by Xijing Hospital.
Recruitment status was:  Recruiting
First Posted : June 14, 2011
Last Update Posted : November 21, 2013
Sponsor:
Information provided by (Responsible Party):

Study Description
Brief Summary:
Adiponectin (Ad) is an abundant protein in human body, and reports have shown that it act as a novel risk factor for brain and heart ischemia injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to these diseases.

Condition or disease
Myocardial Infarction Cerebral Infarction

Detailed Description:
Adiponectin (Ad) is an abundant protein hormone regulatory of numerous metabolic processes, anti-inflammatory, vascular protective, and anti-ischemic properties. Since its 1995 discovery, Ad has garnered considerable attention for its role in diabetic and cardiovascular pathology. Clinical observations have demonstrated the association of hypoadiponectinemia in patients with obesity, cardiovascular disease, and insulin resistance. There is growing evidence supporting Ad can act as a novel risk factor for cardiovascular and cerebrovascular injury. This 5 years follow-up study will focus on serum adiponectin concentration, activity and isoforms in Chinese population and its correlation to cardiovascular and cerebrovascular diseases.

Study Design

Study Type : Observational
Estimated Enrollment : 30000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Serum Adiponectin Concentration, Activity and Isoforms in Chinese Population and Its Correlation to Cardiovascular and Cerebrovascular Diseases
Study Start Date : May 2011
Estimated Primary Completion Date : October 2016
Groups and Cohorts

Group/Cohort
volunteer


Outcome Measures

Primary Outcome Measures :
  1. Number of Participants with major adverse events [ Time Frame: 5 years ]
    Major adverse events included but were not limited to death during the study caused by cardiovascular events or cerebrovascular events.


Secondary Outcome Measures :
  1. blood routine, glucose and lipid profile; ECG; [ Time Frame: 5 years ]
    the tests mentioned above will be taken once per year

  2. serum adiponectin concentration, activity and isoforms [ Time Frame: 5 years ]
    serum adiponectin concentration, activity and isoforms will be monitored once per year.


Biospecimen Retention:   None Retained
blood

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
volunteer
Criteria

Inclusion Criteria:

  • available for 5 years of follow-up study

Exclusion Criteria:

  • Death caused other than cardiovascular and cerebralvascular diseases till the study ends
  • Floating Population
  • Pregnancy, lactation, or child bearing women
  • Tumor
  • Active hepatic disease or hepatic dysfunction, or AST/ALT > 1.5UNL
  • Severe renal dysfunction(Scr > 3 mg/dl or 264μmol/L)
  • Patients with any condition which, in the investigator's judgment, might increase the risk to the subject for any adverse event or abnormal laboratory finding
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01372800


Contacts
Contact: Ling Tao, M.D Ph.D +86-15002955798 lingtao2006@gmail.com

Locations
China, Shaanxi
Xijing Hospital Recruiting
Xi'an, Shaanxi, China, 710032
Contact: Ling Tao, M.D Ph.D    +86-15002955798    lingtao2006@gmail.com   
Principal Investigator: Ling Tao, M.D Ph.D         
Sponsors and Collaborators
Xijing Hospital
More Information

Responsible Party: Xijing Hospital
ClinicalTrials.gov Identifier: NCT01372800     History of Changes
Other Study ID Numbers: xj050503
First Posted: June 14, 2011    Key Record Dates
Last Update Posted: November 21, 2013
Last Verified: November 2011

Keywords provided by Xijing Hospital:
adiponectin
cardiovascular diseases
cerebrovascular diseases

Additional relevant MeSH terms:
Infarction
Myocardial Infarction
Cerebral Infarction
Cerebrovascular Disorders
Ischemia
Pathologic Processes
Necrosis
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Brain Infarction
Brain Ischemia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Stroke